Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know
Does Rapport Therapeutics, Inc. (RAPP) have what it takes to be a top stock pick for momentum investors? Lets find…
1,060$
1,92%
Echtzeit-Aktienkurs Rapt Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Rapt Therapeutics Inc. Aktie
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High?
The consensus price target hints at a 75% upside potential for Rapport Therapeutics, Inc. (RAPP). While empirical research shows that…
RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices
…
Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 104.5% in Rapport Therapeutics, Inc.…
RAPT Therapeutics Inc.: Positive Studiendaten, 250-Mio.-USD-Kapitalerhöhung und Guggenheim sieht 130 % Kurspotenzial
RAPT Therapeutics Inc. (RAPT) ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entdeckung, Entwicklung und Vermarktung neuartiger…
RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria - Slideshow
…
RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript
…
RAPT Therapeutics stock soars after positive data for urticaria treatment By Investing.com
RAPT Therapeutics stock soars after positive data for urticaria treatment…
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based…
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Heres Why
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the companys earnings…
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Heres What You Should Know
The consensus price target hints at a 282.7% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this…
Rapt Therapeutics (RAPT) Upgraded to Buy: Heres What You Should Know
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…
RAPT Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based…
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the…
RAPT Therapeutics stock rises following licensing deal with Jemincare By Investing.com
RAPT Therapeutics stock rises following licensing deal with Jemincare…
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based…
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology…
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based…
Rapport Therapeutics Announces Pricing of Initial Public Offering
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology…
RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
…
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status…
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…